Back to top
more

Acorda Therapeutics, Inc. (ACOR)

(Delayed Data from NSDQ)

$1.71 USD

1.71
1,307,826

+0.01 (0.59%)

Updated Dec 6, 2019 04:00 PM ET

Add to portfolio

3-Hold     3    

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.62%
17.69%
9.40%
5.11%
2.01%
10.65%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

A Value | F Growth | D Momentum | C VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Balance Sheet

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

Research for ACOR

   

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

Fiscal Year End for Acorda Therapeutics, Inc. falls in the month of December.

All items in Millions except Per Share data.

12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Assets          
Cash & Equivalents 446 307 159 359 309
Receivables 23 81 52 31 32
Notes Receivable 0 0 0 0 0
Inventories 29 38 43 36 27
Other Current Assets 30 15 19 24 41
Total Current Assets 528 442 273 451 409
Net Property & Equipment 61 37 34 40 46
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 2 7 5 4
Intangibles 711 717 1,023 614 616
Deposits & Other Assets 0 1 6 5 6
Total Assets 1,300 1,198 1,342 1,116 1,081
Liabilities & Shareholders Equity 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Notes Payable 1 7 6 1 1
Accounts Payable 49 27 27 14 18
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 77 100 105 66 56
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 14 9 10 9 39
Total Current Liabilities 140 144 148 91 114
Mortgages 0 0 0 0 0
Deferred Taxes/Income 7 46 125 54 74
Convertible Debt 319 309 299 297 290
Long-Term Debt 24 26 25 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 197 154 81 72 62
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 688 678 678 513 540
Shareholders Equity 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 1,005 969 921 813 761
Retained Earnings -394 -455 -244 -209 -220
Other Equity 3 7 -13 -0 0
Treasury Stock 2 0 0 0 0
Total Shareholder's Equity 612 520 664 603 540
Total Liabilities & Shareholder's Equity 1,300 1,198 1,342 1,116 1,081
Total Common Equity 612 520 664 603 540
Shares Outstanding 47.50 46.70 46.10 43.10 41.90
Book Value Per Share 12.88 11.13 14.41 13.99 12.89

Fiscal Year End for Acorda Therapeutics, Inc. falls in the month of December.

All items in Millions except Per Share data.

9/30/2019 6/30/2019 3/31/2019 12/31/2018 9/30/2018
Assets          
Cash & Equivalents 254 297 344 446 461
Receivables 18 21 21 23 51
Notes Receivable 0 0 0 0 0
Inventories 27 28 31 29 11
Other Current Assets 16 12 22 30 23
Total Current Assets 314 358 418 528 547
Net Property & Equipment 131 113 83 61 52
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 410 699 706 711 712
Deposits & Other Assets 25 26 27 0 0
Total Assets 880 1,197 1,234 1,300 1,311
Liabilities & Shareholders Equity 9/30/2019 6/30/2019 3/31/2019 12/31/2018 9/30/2018
Notes Payable 1 1 1 1 1
Accounts Payable 27 27 26 49 30
Current Portion Long-Term Debt 8 8 7 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 43 45 46 77 98
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 14 14 17 14 8
Total Current Liabilities 92 94 97 140 136
Mortgages 0 0 0 0 0
Deferred Taxes/Income 3 3 5 7 71
Convertible Debt 326 324 321 319 316
Long-Term Debt 49 51 51 24 25
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 128 192 197 165
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 599 653 667 688 712
Shareholders Equity 9/30/2019 6/30/2019 3/31/2019 12/31/2018 9/30/2018
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 1,015 1,012 1,009 1,005 1,000
Retained Earnings -732 -469 -441 -394 -403
Other Equity -1 3 1 3 4
Treasury Stock 1 1 2 2 2
Total Shareholder's Equity 281 545 567 612 599
Total Liabilities & Shareholder's Equity 880 1,197 1,234 1,300 1,311
Total Common Equity 281 545 567 612 599
Shares Outstanding 48.10 48.10 48.10 47.50 47.40
Book Value Per Share 5.85 11.33 11.78 12.88 12.63